Evidence topics tagged number needed to treat

Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Trying to work out what would count as…

Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…

Journal club: STEP 1 and the treatment-policy estimand Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…

Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…

Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…

Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…

On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Bringing a claim rather than a paper, because the claim is the thing circulating. The…

Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. Bringing a claim rather than a paper, because the claim is the thing circulating.…

Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…

On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it…

Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…

On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…

Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Bringing a claim rather than a paper, because the claim…

Journal club: SURMOUNT-4 and continuation versus withdrawal — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on SURMOUNT-4 and continuation…

Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Reading PIONEER 6 ( N Engl J Med , 2019) for the population rather than the…

Journal club: PIONEER 6 as a safety trial Writing it up because I had to work it out twice and would rather nobody else did. Bringing a claim rather than a paper, because the claim is the thing circulating.…

Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. A narrow question about semaglutide…

Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. Collecting what is known about retatrutide phase 2 obesity paper in one place, because…

Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…

Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…

The question in the title: Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about STEP 3 on…

Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…

Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the…

On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…

Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting; the…

Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on SURMOUNT-1. It is mine, it is…

Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 4 ( JAMA , 2021). Please read…

Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…

The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. Reading SUSTAIN 6 ( N Engl J Med ,…

Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…